Phase 2 trials of chidamide in combination with chemotherapy, such as dexamethasone, ifosfamide, cisplatin, and etoposide (DICE) (NCT03105596), vinorelbine, liposomal doxorubicin, dexamethasone and thalidomide (VDDT) (NCT02733380), R-GDP (NCT03373019), and R-CHOP (NCT03201471) in relapsed or refractory B-NHLs, as well as R-CHOP (NCT02753647) in untreated elderly DLBCL patients, are ongoing. The gene discussed is DDIT3; the disease is diffuse large B-cell lymphoma.